AUTHOR=Yu Yang , Yu Min , Li Yanying , Zhou Xiaojuan , Tian Tian , Du Yijia , Tu Zegui , Huang Meijuan 

TITLE=Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.945620

DOI=10.3389/fonc.2022.945620

ISSN=2234-943X

ABSTRACT=<p><italic>BRAF</italic> gene has been identified as an oncogenic driver and a potential target in various malignancies. <italic>BRAF</italic> fusions are one subtype of <italic>BRAF</italic> alterations with a rare frequency. Here, we first report a previously treated advanced lung adenocarcinoma patient with <italic>de novo SND1-BRAF</italic> fusion who achieves partial response to the MAK inhibitor trametinib. We also provide a literature review on targeted therapies for <italic>BRAF</italic> fusions.</p>